Gilead reported quarterly 4% revenue growth, including 10% HIV product growth. Management raised 2026 revenue guidance by $400 million, which implies 8% HIV therapy and prevention growth (up from 6%).
Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.
Gilead's Yeztugo is a promising new HIV prevention drug, but it is unclear if markets outside the US will embrace this form of therapy.
|
Metric
|
GILD
|
GSK
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.04 | 11.37 | 22.08 |
Price/Book Value | 6.65 | 4.52 | — |
Price/Sales | 5.31 | 2.47 | 6.35 |
Price/Cash Flow | 10.94 | 9.22 | 17.40 |
|
Metric
|
GILD
|
GSK
|
ABBV
|
|---|---|---|---|
Quick Ratio | 1.31 | 0.51 | 0.52 |
Current Ratio | 1.97 | 0.79 | 0.80 |
Interest Coverage | 11.33 | 11.71 | 2.96 |
|
Metric
|
GILD
|
GSK
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 18.35% | 11.47% | 13.37% |
Return on Equity (Normalized) | 49.22% | 44.00% | — |
Return on Invested Capital (Normalized) | 24.23% | 22.62% | 29.17% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Zpknhfnmt | Vmd | $1T | |||
| Johnson & Johnson
JNJ
| Gmmfhxg | Tsww | $580B | |||
| AbbVie Inc
ABBV
| Hjwbgxbx | Ysr | $402B | |||
| Roche Holding AG ADR
RHHBY
| Kjbrfldgp | Hjbw | $331B | |||
| Merck & Co Inc
MRK
| Clghbytr | Zvbxf | $294B | |||
| Novartis AG ADR
NVS
| Rpgncsqvk | Vmwc | $293B | |||
| AstraZeneca PLC
AZN
| Fyhzhmwbd | Wkym | $280B | |||
| Novo Nordisk AS ADR
NVO
| Twdbfznrh | Xyjbz | $197B | |||
| Amgen Inc
AMGN
| Mkhmmfcfxv | Rjrnb | $192B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/558ccc7b-2d37-4a8c-babf-feca8e10da32.jpg)
United States